5 results on '"Marie-Elisabeth Bougnoux"'
Search Results
2. Cryptosporidium spp. Infection in Solid Organ Transplantation
- Author
-
Fanny, Lanternier, Karima, Amazzough, Loic, Favennec, Marie-France, Mamzer-Bruneel, Hendy, Abdoul, Jérome, Tourret, Stéphane, Decramer, Julien, Zuber, Anne, Scemla, Christophe, Legendre, Olivier, Lortholary, Marie-Elisabeth, Bougnoux, and C, Azema
- Subjects
Adult ,Diarrhea ,Male ,0301 basic medicine ,medicine.medical_specialty ,Time Factors ,Adolescent ,030106 microbiology ,030231 tropical medicine ,Antiprotozoal Agents ,Cryptosporidiosis ,Cryptosporidium ,Organ transplantation ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Internal medicine ,medicine ,Humans ,In patient ,Antidiarrheals ,Child ,Aged ,Retrospective Studies ,Transplantation ,biology ,business.industry ,Retrospective cohort study ,Organ Transplantation ,Middle Aged ,Original Clinical Science—General ,biology.organism_classification ,medicine.disease ,3. Good health ,Treatment Outcome ,Immunology ,Female ,medicine.symptom ,Complication ,business ,Solid organ transplantation ,Immunosuppressive Agents - Abstract
BACKGROUND: Diarrhea is a frequent complication of solid organ transplantation. Cryptosporidiosis is classically reported in patients with acquired immunodeficiency syndrome and emerged as a cause of persistent diarrhea in solid organ transplant patients. METHODS: Through the ANOFEL Cryptosporidium National Network and the French Transplantation Society, we collected all cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010 in France. RESULTS: We reported 47 solid organ transplant recipients (41 kidneys) with cryptosporidiosis, mostly men (68%), with a median age of 52 (6-70) years old. Five patients had additional immunodepression favoring cryptosporidiosis (CD40 ligand deficiency [n = 1], human immunodeficiency virus infection [n = 4]). Cryptosporidiosis occurred at a median time of 3.4 (0-19.8) years posttransplant. Exposure to environmental risk factors was found before infection onset in 18 patients. Time between first symptoms and diagnosis was 10 (2-110) days. Four patients had associated extraintestinal location (biliary tract [n = 3] and lung [n = 1]). Thirty-five patients received specific therapy against cryptosporidiosis ie nitozoxanide, 25 in monotherapy, and 10 in association with azithromycin, 13 in association with immunosuppression (IS) reduction. Four patients were cured with IS treatment tapering only. The others patients had neither IS reduction nor specific therapy against cryptosporidiosis. Cryptosporidiosis was complicated by renal failure in 15 patients. Symptoms resolved after a median of 10 days of treatment. Six patients relapsed and 3 died, 1 with evolutive infection. CONCLUSIONS: Cryptosporidiosis is a late posttransplant infection that disseminated to biliar duct or lung in 9% of patients. When limited to digestive tract, infection may resolve without IS reduction.
- Published
- 2017
3. Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency
- Author
-
Vincent Jullien, Magdalena Gerin, Olivier Lortholary, Marie-Elisabeth Bougnoux, Nizar Mahlaoui, Caroline Elie, Fanny Lanternier, and Stéphane Blanche
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Antifungal Agents ,Adolescent ,Pharmacology ,Treatment failure ,medicine ,Humans ,Pharmacology (medical) ,Trough Concentration ,Treatment Failure ,Child ,Voriconazole ,medicine.diagnostic_test ,business.industry ,Immunologic Deficiency Syndromes ,Infant ,Triazoles ,medicine.disease ,Regimen ,Pyrimidines ,Mycoses ,Therapeutic drug monitoring ,Child, Preschool ,Injections, Intravenous ,Primary immunodeficiency ,Female ,Drug Monitoring ,business ,medicine.drug - Abstract
A voriconazole trough concentration (Ctrough)1 mg/L is associated with a higher risk of treatment failure. The aim of this work was to describe the probability of not achieving this target concentration in infants and children receiving intravenous voriconazole.Voriconazole trough concentrations obtained during routine therapeutic drug monitoring over a 5-year period were collected retrospectively from infants and children receiving intravenous voriconazole for presumed or proven invasive fungal infections.Sixty-two trough concentrations were obtained from 6 infants and 10 children. The risk of a Ctrough1 mg/L was 77% and 47%, respectively. Daily doses between 20 and 32 mg/kg were necessary in some patients to achieve a Ctrough1 mg/L, compared with the currently recommended 14-mg/kg regimen.Routine therapeutic drug monitoring is potentially helpful in infants and children receiving voriconazole, even intravenously.
- Published
- 2011
4. Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study
- Author
-
Renaud Snanoudj, Olivier Lortholary, Fanny Lanternier, Christophe Legendre, Rebecca Sberro-Soussan, Sylvain Poirée, Anne Scemla, Marie-Elisabeth Bougnoux, and Anne-Claire Desbois
- Subjects
0301 basic medicine ,Voriconazole ,Transplantation ,medicine.medical_specialty ,business.industry ,Mortality rate ,030106 microbiology ,Case-control study ,Aspergillosis ,medicine.disease ,Kidney transplant ,Original Clinical Science ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Graft survival ,030212 general & internal medicine ,business ,medicine.drug - Abstract
Background Invasive aspergillosis (IA) is a major cause of invasive fungal infection in kidney transplant recipients (KTR), and it has a high mortality rate. However, its impact on patients and graft survival has not been well defined in the current era of voriconazole first-line therapy. Methods We retrospectively collected all cases of KTR-associated IA occurring at Necker Enfants Malades Hospital, Paris, from 2003 to 2013. These cases were compared with a group of controls (1:3) who were matched by age, year of kidney transplantation, and sex. The characteristics of IA were also studied. Results Sixteen patients developed IA after KTR. Most IA cases were limited to the lungs (81.3%), with mild respiratory symptoms in only 53% of the patients. The patients were administered voriconazole (n = 15, 94%) and/or posaconazole (n = 2, 13%). The 12-week and 1-year postinfection survival rates were 94% and 81%, respectively. Compared with the controls (n = 46), patients and death-censored graft survivals rates were significantly lower after IA (P = 0.017 and 0.001, respectively). In the patients with IA, the occurrences of cardiovascular diseases before transplantation (P < 0.0001), delayed graft function (P < 0.0001), and infectious complications (0.0018) were significantly more frequent. Conclusions Even with voriconazole therapy, the prognosis of patients with IA after kidney transplantation is still poor. When the patients survive to IA, they have a high risk of graft loss.
- Published
- 2016
5. Clinical Course of Intestinal Microsporidiosis in Renal Transplant Recipients
- Author
-
Fanny Lanternier, Anne Scemla, Renaud Snanoudj, C. Legendre, Marie-Elisabeth Bougnoux, Julien Zuber, Florence Aulagnon, and Olivier Lortholary
- Subjects
Transplantation ,medicine.medical_specialty ,Intestinal microsporidiosis ,business.industry ,Renal transplant ,Internal medicine ,Clinical course ,Medicine ,business ,Gastroenterology - Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.